Menu Eline, Asosingh Kewal, Indraccolo Stefano, De Raeve Hendrik, Van Riet Ivan, Van Valckenborgh Els, Vande Broek Isabelle, Fujii Nobutaka, Tamamura Hirokazu, Van Camp Ben, Vanderkerken Karin
Department of Hematology and Immunology, Vrije Universiteit Brussel, Brussels, Belgium.
Haematologica. 2006 May;91(5):605-12. Epub 2006 Apr 19.
Multiple myeloma (MM) is a lethal plasma cell cancer characterized by the monoclonal growth of cells in the bone marrow. To reach the bone marrow, MM cells need to be attracted by chemokines. Recently, it has been shown that chemokines can also be involved in the growth of several cancer types. Stromal cell derived factor 1a (SDF1alpha) or CXCL12 is known to play an important role as a chemokine for hematopoietic progenitor cells and human MM cells. We studied the effects of SDF1a in the 5TMM murine model.
The in vitro effects of SDF1alpha were analyzed by gelatin zymography, adhesion, migration, proliferation, and chemoinvasion assays and by blockade with the CXCR4 inhibitor, 4F-benzoyl-TN14003. In vivo, diseased mice were treated with either vehicle or 4F-benzoyl-TN14003.
In vitro SDF1alpha was capable of attracting both 5T2MM and 5T33MM cells and inducing a 1.6-fold increase in MMP9 production by the 5TMM cells, which was correlated with an increased invasive capacity. In addition, SDF1alpha induced a 20% increase in DNA synthesis in the 5TMM cells. All these effects could be blocked by the CXCR4 inhibitor, 4Fbenzoyl- TN14003. An in vivo study in the 5T33MM model showed that blocking CXCR4 led to a 20% reduction in bone marrow tumor load.
These data demonstrate that SDF1alpha/CXCR4 is involved in the homing and the expansion of MM cells. Blocking CXCR4 could be useful in synergy with other anti-neoplastic treatments targeting the bone marrow microenvironment.
多发性骨髓瘤(MM)是一种致命的浆细胞癌,其特征为骨髓中细胞的单克隆生长。为了到达骨髓,MM细胞需要被趋化因子吸引。最近研究表明,趋化因子也可能参与多种癌症类型的生长。基质细胞衍生因子1a(SDF1α)或CXCL12作为造血祖细胞和人MM细胞的趋化因子发挥重要作用。我们研究了SDF1a在5TMM小鼠模型中的作用。
通过明胶酶谱法、黏附、迁移、增殖和化学侵袭试验以及用CXCR4抑制剂4F-苯甲酰-TN14003进行阻断,分析SDF1α的体外作用。在体内,患病小鼠用赋形剂或4F-苯甲酰-TN14003治疗。
体外,SDF1α能够吸引5T2MM和5T33MM细胞,并使5TMM细胞的MMP9产生增加1.6倍,这与侵袭能力增强相关。此外,SDF1α使5TMM细胞的DNA合成增加20%。所有这些作用都可被CXCR4抑制剂4F-苯甲酰-TN14003阻断。在5T33MM模型中的体内研究表明,阻断CXCR4可使骨髓肿瘤负荷降低20%。
这些数据表明SDF1α/CXCR4参与MM细胞的归巢和扩增。阻断CXCR4与针对骨髓微环境的其他抗肿瘤治疗联合使用可能有用。